In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.

Faculty

• Debbie Shawcross (Moderator)
• Rajiv Jalan (Faculty)
• Sara Montagnese (Faculty)
• Elliot Tapper (Faculty)

This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).

Related episodes

• EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?
• EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
• EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
• EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within
• EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?
• EASL Studio S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?

All EASL Studio Podcasts are available on EASL Campus.

This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions.

Faculty

• Patrizia Burra (Moderator)
• Maria Buti (Faculty)
• Peter Jepsen (Faculty)
• Shira Zelber-Sagi (Faculty)

Related episodes

• EASL Studio S6E1: Do we solve MASLD by treating obesity?
• EASL Studio from EASL Congress 2023: The battle to reduce alcohol harms… EASL’s new policy
• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S2E2: Fats or carbs, who is the real villain?

All EASL Studio Podcasts are available on EASL Campus.

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.

Faculty

• Aleksander Krag (Moderator)
• Aftab Ala (Faculty)
• Pavel Strnad (Faculty)
• Alice Turner (Faculty)

Related episodes

• EASL Studio from EASL Congress 2023: Clinical trials in rare diseases – opportunities and challenges
• EASL Studio from ILC 2022: Rare Liver Diseases – A growing landscape of opportunities and challenges

This episode is scheduled in honour of the Rare Disease Day (29 February).

All EASL Studio Podcasts are available on EASL Campus.

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research?

Faculty

• Paolo Angeli (Moderator)
• Guadalupe Garcia-Tsao (Faculty)
• Valérie Paradis (Faculty)
• Thomas Reiberger (Faculty)

Related episodes

• EASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approach
• EASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclature
• EASL Studio S4E4: JHEP Live: Is the term ‘decompensated cirrhosis’ outdated?

All EASL Studio Podcasts are available on EASL Campus.

In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.

Faculty

• Thomas Berg (Moderator)
• Katie Kelley (Faculty)
• Daniela Sia (Faculty)
• Juan Valle (Faculty)

This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.

Related episodes

• EASL Studio S5E13: Basics in decision-making for liver cancer treatment
• EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
• EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
• EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?

All EASL Studio Podcasts are available on EASL Campus.

The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management.

Faculty

• Pierre-Emmanuel Rautou (Moderator)
• Virginia Hernández-Gea (Faculty)
• Patrick Kamath (Faculty)
• Wim Laleman (Faculty)

Related episodes:

• EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome

All EASL Studio Podcasts are available on EASL Campus.

Our speakers explore the latest insights into the adipose tissue-liver axis, focusing on weight-reducing drugs’ current status and the crucial question of who should prescribe them and how efficacy should be monitored. They debate the implications of these drugs, their expected outcomes, and their integration into the toolkit of hepatologists.

Don’t miss this opportunity to grasp the evolving dynamics between obesity treatment and MASLD management!

Faculty

• Sven Francque (Moderator)
• Willem Pieter Brouwer (Faculty)
• Cyrielle Caussy (Faculty)
• Dimitris Papamargaritis (Faculty)

This episode is scheduled following the United Kingdom’s National Obesity Awareness Week.

Related episodes:

• EASL Studio S5E7: Why bother with diet and exercise when an injection will suffice?
• EASL Studio S4E8: The central role of alcohol and food policies on liver health
• EASL Studio S2E2: Fats or carbs, who is the real villain?

All EASL Studio Podcasts are available on EASL Campus.

Join us for a wrap-up of EASL Studio’s season and a preview of what is to come in 2024! In this special episode, we reminisce about the year’s top hepatology breakthroughs and controversies. This festive discussion highlights the best of the past while offering an exciting glimpse into the future of the evolving world of liver health.

Faculty

• Aleksander Krag (Moderator)
• Thomas Berg (Faculty)
• Ahmed Elsharkawy (Faculty)
• Debbie Shawcross (Faculty)

All EASL Studio Podcasts are available on EASL Campus.

Hepatic encephalopathy (HE) is a common reversible complication of advanced liver disease characterised by a spectrum of neuropsychiatric abnormalities. Due to its insidious onset, most patients only seek treatment once complications develop, resulting in it being an underdiagnosed and underestimated condition.

This EASL Studio episode, organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN), explores the patient journey and treatment options.

Faculty

• Debbie Shawcross (Moderator)
• Christian Labenz (Faculty)
• Steve Rodrigues (Faculty)
• Dominique Thabut (Faculty)

This EASL Studio is supported by Norgine. EASL has received no input from Norgine with regards to the content of this programme.

Related episode

• EASL Studio S2E7: JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathy

All EASL Studio Podcasts are available on EASL Campus.

With cases of hepatocellular carcinoma on the rise and representing the end stage of many chronic liver diseases, the treatment of liver cancer has become one of the most dynamic areas in hepatology. The focus of this episode is on answering practical clinical questions, examining trial data, and sharing clinical insights that may be useful for decision-making in daily clinical practice.

Faculty

• Tom Lüdde (Moderator)
• Christoph Roderburg (Faculty)
• Anna Saborowski (Faculty)
• Arndt Vogel (Faculty)

This EASL Studio is supported by AstraZeneca and Eisai. EASL has received no input from AstraZeneca or Eisai with regards to the content of this programme.

Related episodes

• EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
• EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
• EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?

All EASL Studio Podcasts are available on EASL Campus.